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Application of cholesterol-free liposomes as carriers for anticancer drugs is hampered, in part, because of standard pH gradient based
loading methods that rely on incubation temperatures above the phase transition temperature (Tc) of the bulk phospholipid to promote drug
loading. In the absence of cholesterol, liposome permeability is enhanced at these temperatures which, in turn, can result in the collapse of the
pH gradient and/or unstable loading. Doxorubicin loading studies, for example, indicate that the drug could not be loaded efficiently into
cholesterol-free DSPC liposomes. We demonstrated that this problem could be circumvented by the addition of ethanol as a permeability
enhancer. Doxorubicin loading rates in cholesterol-free DSPC liposomes were 6.6-fold higher in the presence of ethanol. In addition, greater
than 90% of the added doxorubicin was encapsulated within 2 h at 37 jC, an efficiency that was 2.3-fold greater than that observed in the
absence of ethanol. Optimal ethanol concentrations ranged from 10% to 15% (v/v) and these concentrations did not significantly affect
liposome size, retention of an aqueous trap marker (lactose) or, most importantly, the stability of the imposed pH gradient. Cryo-transmission
electron micrographs of liposomes exposed to increasing concentrations of ethanol indicated that at 30% (v/v) perturbations to the lipid
bilayer were present as evidenced by the appearance of open liposomes and bilayer sheets. Ethanol-induced increased drug loading was
temperature-, lipid composition- and lipid concentration-dependent. Collectively, these results suggest that ethanol addition to preformed
liposomes is an effective method to achieve efficient pH gradient-dependent loading of cholesterol-free liposomes at temperatures below the
Tc of the bulk phospholipid.
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1,2-diarachidoyl-sn-glycero-3-phosphatidylcholine; dox, doxorubicin; dpm, disintegrations per minute; DPPC, 1,2-dipalmitoyl-sn-glycero-3-phosphatidylcho-
line; DSPC, 1,2-distearoyl-sn-glycero-3-phosphatidylcholine; DSPE, 1,2-distearoyl-sn-glycero-3-phosphatidylethanolamine; PEG, poly(ethylene glycol); 3[H],
tritium radiolabel; H2SO4, sulfuric acid; HEPES, N-[2-hydroxyethyl]piperazine-NV-[2-ethanesulfonic acid]; HBS, HEPES buffered saline; LUV, large
unilamellar vesicle; MLV, multilamellar vesicle; PC, phosphatidylcholine; PE, phosphatidylethanolamine; PK, pharmacokinetic; QELS, quasielastic light
scattering; SDS, sodium dodecyl sulfate; Tc, phase transition temperature; v/v, volume to volume ratio
* Corresponding author. Department of Advanced Therapeutics, British Columbia Cancer Agency, BC Cancer Research Centre, 600 West 10th Avenue,
Vancouver, BC, Canada V5Z 4E6. Tel.: +1-604-877-6098x3191; fax: +1-604-877-6011.
E-mail address: mbally@bccancer.bc.ca (M.B. Bally).
N. Dos Santos et al. / Biochimica et Biophysica Acta 1661 (2004) 47–60481. Introduction efficiency of such drugs is to enhance the drug partition-Within the last decade, significant improvements in
liposome technology have generated agents suitable for
human use. Liposomal anti-cancer agents currently on the
market include DoxilR (doxorubicin), DaunoXomeR
(daunorubicin) and DepoCytR (cytosine arabinoside)
[1–3]. These agents have demonstrated enhanced thera-
peutic activity and/or reduced toxicity relative to the free
drug form, indicating that encapsulation of drugs in lipid
based carriers is beneficial. Unfortunately, designing li-
posome carriers has proven to be an empirical process.
Not only is it important to ensure that drug uptake and
stability is achieved in a given liposome formulation, but
also that the encapsulated drug is bioavailable over a
time frame that is appropriate to achieve maximum
therapeutic effects [4]. This delicate balance has been
difficult to achieve. It is evident that not all drugs are
amenable to encapsulation in lipid based carriers with
current technologies. Thus development of novel methods
to improve drug loading and, in turn, to investigate
appropriate release rates for a given drug remains a
fundamental hurdle in the development of other antican-
cer drug formulations.
Recent work from this laboratory has shown that
liposomes composed of distearoylphosphatidylcholine
(DSPC) and low amounts of distearoylphosphatidyletha-
nolamine conjugated poly(ethylene glycol) (DSPE-PEG)
retained idarubicin better than conventional cholesterol-
containing liposomes in vivo [5]. Incorporating hydrophil-
ic polymers, such as PEG, was sufficient to improve the
stability of the liposomes, as judged by in vivo pharma-
cokinetic (PK) assessments. In liposomes composed of
phospholipids, the absence of cholesterol results in a
formulation that can be exquisitely sensitive to changes
in temperature and osmotic gradients. These attributes are
controlled in part by the presence of grain boundaries,
lipid domains and disc formation [6–8], all of which are
absent in liposomes containing > 30% cholesterol.
The studies described in this report investigated
anthracycline encapsulation within DSPC/DSPE-PEG lip-
id mixtures through the use of transmembrane pH gradi-
ent-based loading methods. Although anthracyclines such
as doxorubicin and idarubicin have a similar structure,
they have significantly different octanol/buffer concentra-
tion ratios [9]. Increased idarubicin uptake in liposomes
may be directly attributed to idarubicin’s higher relative
hydrophobicity [10], aiding in its transbilayer movement
which, in turn, results in increased loading rates as well
as efficient loading at lower temperatures when compared
to doxorubicin. Although our rationale to characterize
cholesterol-free liposomes composed of gel phase DSPC
was to effectively improve retention of drugs that exhibit
increased permeability across the bilayer, there is also an
interest in assessing drugs that may exhibit decreased
bilayer permeability. An approach to improve the loadinging and/or permeability of the lipid bilayer.
Several methods have been shown to increase membrane
permeability including incorporation of cholesterol below
the Tc of the bulk phospholipid [11], PEG-modified lipids
[12,13], and lysophospholipids [14]. Simpler methods, such
as the addition of short-chain alcohols [15–17] or surfac-
tants, such as detergents [18], have also been applied.
Considering that the interaction of short-chain alcohols, such
as ethanol, with lipid bilayers is well documented and it is
easily removed from samples, this was identified as a
preferred method. Many groups have investigated the spe-
cific interaction of ethanol with lipid bilayers [19–22].
Addition of ethanol to lipid membranes results in an increase
in the dielectric constant [23], dehydration of the phospho-
lipid head groups [24], and an increase in ion permeability
[17]. It should also be noted that ethanol has been exten-
sively used in the preparation of liposomes for improving
transdermal liposomal drug delivery [25], improving encap-
sulation of proteins [26] and gene-based agents [27,28],
increasing trapped volume [29], and ensuring compositional
homogeneity [30].
In the studies described herein, doxorubicin’s low perme-
ability made it difficult to effectively encapsulate the drug in
cholesterol-free liposomes. Therefore, ethanol was utilized at
concentrationswellbelowthatrequiredtocollapsetheimposed
pHgradient in order to increase drug loading rates. The results
suggest that ethanol can be used as an effective strategy to
overcome difficulties with drug loading, especiallywhen con-
sidering the potential of cholesterol-free formulations for drug
delivery.2. Materials and methods
2.1. Materials
Dipalmitoylphosphatidylcholine (DPPC), DSPC and dia-
rachidoylphosphatidylcholine (DAPC) lipids and DSPE-
PEG lipids (molecular weight 2000) were obtained from
Avanti Polar Lipids, (Alabaster, AL, USA). Ethyl alcohol
(99.9% v/v) was manufactured by Commercial Alcohols
(Chatham, ON, Canada). HEPES, citric acid, sephadex G-
50 (medium), 3[H]-cholesteryl hexadecyl ether (CHE), cho-
lesterol (CH) and 14[C]-lactose were obtained from NEN Life
Science Products (Oakville, ON, Canada). 14[C]-Methyl-
amine hydrochloride was obtained from Amersham Pharma-
cia Biotech (Oakville, ON, Canada). Picofluoro-15
scintillation fluid was obtained from Packard Bioscience
(Groningen, The Netherlands). The anthracyclines idarubicin
hydrochloride and epirubicin hydrochloride (Pharmacia and
Upjohn, Boston, MA, USA), doxorubicin hydrochloride
(Faulding, Montreal, QC, Canada), and daunorubicin hydro-
chloride (Novopharm, Toronto, ON, Canada) were manufac-
tured by the indicated companies and obtained from British
Columbia Cancer Agency (Vancouver, BC, Canada).
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DSPC/DSPE-PEG2000 (95:5 mole ratio) and DSPC/CH/
DSPE-PEG2000 (50:45:5 mole ratio) liposomes were pre-
pared by the extrusion technique [31]. Briefly, lipids were
dissolved in chloroform and mixed together in a test tube at
appropriate molar ratios. 3[H]-CHE was added as a non-
exchangeable, non-metabolizable lipid marker [32,33]. The
chloroform was evaporated under a stream of nitrogen gas
and the sample was placed in a high vacuum overnight. The
lipid films were rehydrated in citrate (300 mM citric acid, pH
4.0) by gentle mixing and heating. The newly formed multi-
lamellar vesicles (MLVs) were passed 10 times through an
extruding apparatus (Northern Lipids, Vancouver, BC, Can-
ada) containing two stacked 100-nm polycarbonate filters.
The mean diameter and size distribution of each liposome
preparation (prior to addition of ethanol or drugs), analyzed
by a NICOMP model 270 submicron particle sizer (Pacific
Scientific, Santa Barbara, CA, USA) operating at 632.8 nm,
was typically 100F 30 nm.
2.3. Remote loading of anthracyclines
The remote loading procedure has been well characterized
for weak bases such as anthracyclines [34]. Following
hydration of lipid films in citrate (300 mM citric acid; pH
4.0), extrusion and size determination, liposomes were
passed down a sephadex G-50 column (10 1.5 cm) equil-
ibrated with HEPES buffered saline (HBS; 20 mM HEPES,
150 mM NaCl, pH 7.4) to exchange the external buffer. The
eluted liposomes had a transmembrane pH gradient, pH 4.0
inside and pH 7.4 outside. Ethanol and drugs were added to
the liposome preparation (5 mM total lipid concentration) at a
0.2 drug-to-lipid mole ratio at varying incubation temper-
atures. Note that in all cases, ethanol was added following
drug addition to prevent exposure of liposomes to excessively
high ethanol concentrations.
For drug loading rate determination, 100 Al aliquots were
added to mini spin columns at 1, 2, 5, 10, 15, 30, 60 and 120
min following remote loading. Spin columns were prepared
by adding glass wool to a 1-cc syringe and sephadex G-50
beads packed by centrifugation (680 g, 2 min). Following
addition of the sample to the column, the liposome fraction
was collected in the void volume (centrifugation 680 g, 2
min) and both lipid and drug content were analyzed. The
lipid concentration was measured by 3[H]-CHE radioactive
counts and drug concentration was determined by measur-
ing the absorbance at 480 nm (HP 8453 UV–visible
spectroscopy system, Agilent Technologies Canada, Mis-
sissauga, ON, Canada) in a 1% Triton X-100 solution and
compared to a standard curve.
2.4. Drug and liposomal membrane association studies
The amount of drug associated with liposomes prepared
without a pH gradient was determined. These studies were
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the presence of ethanol on drug association with lipid
membranes. Based on the experimental design, the drug
concentration is a collective measurement of drug that has
equilibrated across the lipid membrane in the aqueous space,
drug associated with the lipid membrane through partition-
ing, head group and electrostatic interactions. In the absence
of a pH gradient, it is believed that most of the drug is
associated with the membrane, although drug precipitation
in the aqueous space cannot be disregarded. DSPC/DSPE-
PEG2000 (95:5 mole ratio) and DSPC/CH/DSPE-PEG2000
(50:45:5 mole ratio) liposomes were prepared as described
in Section 2.2, hydrated in HBS, pH 7.4, and extruded.
Drugs (idarubicin, daunorubicin, doxorubicin or epirubicin)
and/or ethanol was combined with liposomes (5 mM total
lipid concentration) at a 0.2 Amol drug/Amol phospholipid
ratio and incubated at 40 jC for 60 min. One-hundred-
microliter aliquots were passed down mini spin columns
(680 g, 2 min) and both lipid and drug concentrations
were measured by radioactive counts (TriCarbR Model
1900TR liquid scintillation analyzer, Meriden, CT, USA)
and an anthracycline extraction assay (Section 2.8) followed
by fluorescence spectrometer detection, respectively.
2.5. Determination of pH gradient and percent
14[C]-lactose retention
To measure the transmembrane pH gradient, 14[C]-me-
thylamine was added to liposomes and incubated with
increasing concentrations of ethanol (0%, 5%, 10%, 20%,
and 30% v/v) for 60 min at 37 jC. Samples were passed
down sephadex G-50 mini spin columns to separate lipo-
some encapsulated 14[C]-methylamine. The pH gradient was
calculated as previously determined [35] by the following
equation:
DpH ¼  log½H
þ
in
½Hþout ¼ log
ðCH3NH3Þþin
ðCH3NH3Þþout
ð1Þ
To determine the percent lactose retention, lipid films
were hydrated in HBS (pH 7.4) containing tracer quantities
of 14[C]-lactose. Following extrusion, liposomes were
incubated at 40 jC with increasing ethanol concentrations
(0–30%) for 60 min and 100-Al aliquots were passed
down sephadex G-50 mini spin columns. Both lipid and
lactose concentrations were determined using specific
activity counts of 3[H]-CHE and 14[C]-lactose.
2.6. Cryo-transmission electron microscopy (cryo-TEM)
Cholesterol-free liposomes were analyzed by cryo-
TEM, the method employed and interpretation of liposome
images has been previously described [36]. Briefly, in a
climate chamber, a drop of the liposomes solution was
placed on a copper grid containing a polymer film and
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The sample was flash frozen in ethane allowing the film to
vitrify, an essential step to prevent crystal formation. The
copper grid containing the sample was transferred to an
electron microscope at liquid nitrogen temperature where it
was analyzed.
2.7. Plasma elimination of liposomes
In vivo drug release of anthracyclines encapsulated in
liposomes in the absence and presence of 10% (v/v)
ethanol was evaluated. For PK analysis, samples were
prepared and remote loaded as mentioned and subse-
quently concentrated to 16.5 mM lipid concentration with
cross-flow cartridges (500,000 MWCO) manufactured by
A/G Technology Corp. (Needham, MA, USA).
Female Balb/c mice, 20–22 g, breeders were pur-
chased from Charles River Laboratories (St. Constant,
QC, Canada) and bred in house. Mice were housed in
microisolator cages and given free access to food and
water. All animal studies were conducted according to
procedures approved by the University of British Colum-
bia’s Animal Care Committtee and in accordance with the
current guidelines established by the Canadian Council of
Animal Care.
3[H]-CHE radiolabeled liposome samples were admin-
istered intravenously into the lateral tail vein of female
Balb/c mice. Mice were injected with 33 Amol/kg drug
and 165 Amol/kg lipid (0.2 Amol drug/Amol phospholi-
pid). At various time points post drug administration,
blood was collected by tail nick or cardiac puncture.
Plasma lipid and drug concentrations were quantified by
liquid scintillation counting and an anthracycline extrac-
tion assay (Section 2.8) followed by fluorescence spec-
trometer detection, respectively.
2.8. Anthracycline extraction assay
Doxorubicin, daunorubicin, epirubicin or idarubicin
was extracted from plasma or buffer samples with a
standard extraction assay [37]. Briefly, an aliquot of
plasma was added to a 16 100 mm test tube made
up to 800 Al with distilled water. Subsequently, 100 Al of
both SDS and 10 mM H2SO4 was added, vortexed and
followed by the addition of 2 ml of 1:1 isopropranol/
chloroform. Samples were placed in  80 jC for 1 h. All
tubes were equilibrated to room temperature, vortexed
and centrifuged at 1000 g for 10 min. The bottom
organic phase was carefully transferred into a clean test
tube and samples measured on an LS 50B luminescence
spectrometer (Perkin-Elmer, Beaconsfield, Buckingham-
shire, England) using an excitation wavelength of 480
(5-nm bandpass) and an emission wavelength of 550 (10-
nm bandpass). The doxorubicin extraction efficiency for
plasma samples was determined to be > 90% and slightly
lower for tissue samples.2.9. Pharmacokinetic modeling and statistical analysis
The plasma elimination data was modeled using Win
NONLIN (version 1.5) pharmacokinetic software (Pharsight
Corporation, Mountain View, CA, USA) to calculate PK
parameters of liposomal doxorubicin. The mean plasma area
under the curve (AUC) for a defined time interval was
determined by the standard trapezoidal rule. All data values
are reported as meanF standard deviation (S.D.). A stan-
dard one-way analysis of variance (ANOVA) was used to
determine statistically significant differences of the means.
For multiple comparisons, post-hoc analysis using the
Tukey–Kramer test was used. P < 0.05 was considered
significant.
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3.1. Drug uptake studies of anthracyclines in cholesterol-
free liposomes
Previous studies demonstrated that encapsulation of
idarubicin in DSPC/DSPE-PEG2000 liposomes (prepared in
pH 4.0 citrate buffer and exchanged into a pH 7.4 HBS
buffer) was optimal between 37 and 40 jC, a temperature
range below the phase transition temperature of DSPC [5].
In contrast to idarubicin, doxorubicin could not be efficient-
ly loaded under the same conditions (Fig. 1A, open circles).
In fact, less than 25% of the added doxorubicin accumulated
in DSPC/DSPE-PEG2000 liposomes over the 2-h time course
at 40 jC. The rate of daunorubicin loading (open triangles)
was faster than doxorubicin, but slower than idarubicin. It
should be noted that the rate of drug loading in the
cholesterol-free liposomes increased when the loading tem-
perature was elevated (data not shown). For idarubicin,
daunorubicin and doxorubicin, 100% loading was achieved
in DSPC/DSPE-PEG2000 liposomes within 2 min when the
incubation temperature was higher than the Tc of DSPC
(55 jC). For idarubicin the loading efficiency at 60 jC is
> 95% after a 2-min incubation, but less the > 30% after 1 h,
suggesting a collapse in the pH gradient used to promote
loading and/or re-equilibration of drug across a leaky
membrane.
3.2. Plasma elimination studies of anthracyclines encapsu-
lated in cholesterol-free liposomes
Lipid membranes are selectively permeable and permit
the bidirectional flow of solutes, such as drugs, and thus we
investigated whether the observed differences in drug load-
ing rates at 40 jC would be an indication of drug elimina-
tion rates in vivo. Idarubicin, daunorubicin and doxorubicin
were remotely loaded into DSPC/DSPE-PEG2000 (95:5
mole ratio) liposomes and injected into the lateral tail vein
of female Balb/c mice at 33 Amol/kg drug and 165 Amol/kg
lipid doses (0.2 Amol drug/Amol lipid ratio). Drug and lipid
Fig. 2. Influence of drug hydrophobicity on liposomal membrane
association in cholesterol-free and cholesterol-containing liposomes.
DSPC/DSPE-PEG2000 (95:5 mole ratio, open bars) and DSPC/CH/DSPE-
PEG2000 (50:45:5 mole ratio, filled bars) liposomes exhibiting no pH
gradient were incubated with the anthracyclines idarubicin, daunorubicin,
doxorubicin and epirubicin at 40 jC for 60 min (lipid concentration was 5
mM). One-hundred-microliter aliquots were passed down mini spin
columns and analyzed for lipid and drug concentrations by liquid
scintillation counting and an anthracycline extraction assay (Section 2.8)
followed by luminescence spectrometer detection. Inset: The influence of
ethanol on doxorubicin liposomal membrane association. DSPC/DSPE-
PEG2000 (95:5 mole ratio, open bars) liposomes exhibiting no pH gradient
were incubated with doxorubicin and increasing concentrations of ethanol
(0–15% v/v) at 40 jC for 60 min. Lipid and drug concentrations were
measured as detailed above and in Section 2.
Fig. 1. (A) Time course of uptake of anthracyclines in cholesterol-free
liposomes. DSPC/DSPE-PEG2000 (95:5 mole ratio) liposomes (with
transmembrane pH gradient, pH 4 inside, 7.4 outside) were incubated with
idarubicin (5), daunorubicin (4) or doxorubicin (o) at 40 jC (drug-to-
lipid mole ratio = 0.2). At various time points, 100-Al aliquots of sample
were passed down mini spin columns and subsequently analyzed for drug
and lipid concentrations as described in Section 2. Lipid concentration for
studies was 5 mM. (B) Plasma elimination of anthracyclines encapsulated
in DSPC/DSPE-PEG2000 liposomes. Large unilamellar vesicles radio-
labeled with 3[H]-CHE were encapsulated with idarubicin (5), daunor-
ubicin (4) or doxorubicin (o) by remote loading. Liposomal drugs were
administered intravenously via the dorsal tail vein of Balb/c mice at a dose
of 33 Amol/kg drug and 165 Amol/kg total lipid (0.2 drug-to-lipid mole
ratio). Blood was collected at various time points following administration.
Plasma was assayed for lipid and doxorubicin concentration as described in
Section 2.
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dures and described in methods (Sections 2.7 and 2.8), and
plotted as the Amol drug/Amol lipid ratio versus time post
administration (Fig. 1B). Plasma lipid elimination profiles
were similar for all samples (results not shown) and there-
fore the calculated drug-to-lipid mole ratio provides an
indication of the amount of drug released from the lip-
osomes over time after injection. Significant differences
(P < 0.05) in plasma drug-to-lipid mole ratio were observed
at 24 h post drug administration. Values of 0.02, 0.05 and
0.14 Amol drug/Amol lipid were measured for idarubicin,daunorubicin and doxorubicin encapsulated in cholesterol-
free liposomes at this time point. As predicted, the release of
anthracyclines from liposomes could be related to drug
loading rates.
3.3. Drug and liposomal membrane association of
anthracyclines
To this point, we have established a connection between
anthracycline drug loading rates at 40 jC, a temperature
below the Tc of the bulk phospholipid, and the retention of
anthracyclines encapsulated in cholesterol-free liposomes in
vivo. Doxorubicin’s lower drug loading rate and increased
retention in cholesterol-free liposomes as compared to both
daunorubicin and idarubicin is consistent with doxorubicin’s
lower partition coefficient relative to idarubicin [10], as
illustrated in Fig. 2. We measured the amount of drug
associated with cholesterol-free (open bars) and cholester-
ol-containing (filled bars) liposomes prepared without a pH
gradient; the measured values shown should be taken to
represent liposomal membrane association and it should not
be viewed as a direct measurement of drug partitioning.
Based on the experimental conditions, the amount of drug
measured is a collective measurement of drug that has
equilibrated across the lipid membrane in the aqueous space
(or precipitated), drug associated with the lipid membrane
through partitioning, hydrophobic and electrostatic interac-
Fig. 3. Ethanol-induced increases in drug loading rates in liposomes. DSPC/
CH/DSPE-PEG2000 (50:45:5 mole ratio, squares) and DSPC/DSPE-
PEG2000 (95:5 mole ratio, circles) liposomes (with transmembrane pH
gradient, pH 4 inside, 7.4 outside) were incubated at 37 jC with
doxorubicin (0.2 drug-to-lipid mole ratio) in the absence (open symbols)
and presence (closed symbols) of 10% (v/v) ethanol. At various time points,
100-Al aliquots of sample were passed down mini spin columns and
subsequently analyzed for drug and lipid concentrations as described in
Section 2.
Fig. 4. Influence of ethanol concentration on the accumulation of
doxorubicin in cholesterol-free liposomes. DSPC/DSPE-PEG2000 (95:5
mole ratio) liposomes (with transmembrane pH gradient, pH 4 inside, 7.4
outside) were incubated at 37 jC with doxorubicin and increasing
concentrations of ethanol. At 1 h post drug loading, aliquots were passed
down mini spin columns and the eluted fraction was analyzed for drug and
lipid concentration by methods outlined in Section 2.
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most of the drug is associated with the membrane, although
drug equilibration into the aqueous space cannot be dis-
regarded. The results in Fig. 2 demonstrate that the anthra-
cycline liposomal membrane association is reduced by a
factor of more than 2 when the DSPC/DSPE-PEG2000 lip-
osomes are prepared with 45 mol% cholesterol. This result
is consistent with the understanding that cholesterol
decreases the partitioning of drugs into bilayers, an effect
that has been shown by others to be greater at lower
temperatures [38]. For liposomes prepared without choles-
terol, the drug liposomal membrane association data (shown
as the amount of drug associated per micromole of liposo-
mal lipid) suggests that the level of idarubicin associated
was almost 10-fold greater than that observed for doxoru-
bicin or epirubicin, the most hydrophilic anthracyclines
evaluated. The liposomal membrane association behaviour
of daunorubicin is intermediate between idarubicin and
doxorubicin.
These results have a number of interesting implications.
We have focused here on one aspect that is built on the
suggestion that enhancing doxorubicin membrane associa-
tion and/or enhancing membrane permeability of the lipid
bilayer, under conditions that do not affect the stability of
the pH gradient, could increase drug loading rates of
doxorubicin in cholesterol-free liposomes. As the results
from our drug liposomal membrane association assay are
consistent with relative hydrophobicities of the anthracy-
clines [9,10], this assay was utilized to evaluate whether
doxorubicin membrane association could be enhanced with
the addition of ethanol at 40 jC. The results are summarized
in the inset graph of Fig. 2. In the presence of ethanol (0–
15% v/v), the drug-to-lipid ratio was between 0.007 and0.008 Amol dox/Amol lipid, approximately two-fold higher
than in the absence of ethanol (P < 0.01). Note that calcu-
lations based on the equilibration of drug concentration
across lipid membranes at 1 mM doxorubicin, assuming
no membrane partitioning, were expected to yield 0.002
Amol dox/Amol lipid; thus, it can be suggested that the
majority of the associated drug is membrane-bound. There
were no significant differences in doxorubicin membrane
association as the ethanol concentrations increased from 5%
to 15% v/v. It needs to be noted that the methods used do
not account for membrane association at equilibrium. Non-
equilibrium conditions are introduced during the separation
of lipid-associated and free drug on the G-50 sephadex spin
columns. If membrane-associated ethanol is removed while
being passed down the column, this may result in a loss in
membrane-associated doxorubicin and an underestimation
of the level of membrane association.
3.4. Influence of ethanol on doxorubicin loading in
liposomes
As summarized in Fig. 3, the rate and extent of doxoru-
bicin loading at 37 jC was significantly increased by
addition of ethanol (10%, v/v) to DSPC/DSPE-PEG2000
liposomes. Greater than 90% encapsulation efficiency was
achieved following a 2-h incubation at 37 jC, a value that
was 2.3-fold higher than that observed in the absence of
ethanol. For DSPC/DSPE-PEG2000 liposomes, initial drug
loading rates were 6.40 (nmol dox/Amol lipid) min 1 as
compared to 1.40 (nmol dox/Amol lipid) min 1 in the
presence and absence of ethanol, respectively. In the ab-
sence of ethanol, liposomes composed of DSPC/CH/DSPE-
PEG2000 exhibited improved encapsulation efficiencies
Table 1
The influence of ethanol concentration on size, percent lactose retained and
pH gradient in DSPC/DSPE-PEG2000 (95:5 mole ratio) liposomes
Ethanol
concentration
Liposome
size (nm)a
Lactose retention
(% of control)b
pH gradientc
(%) Precolumn Postcolumn
0 107 109 100F 7 2.77F 0.23
5 113 112 103F 9 2.80F 0.24
10 116 112 97F 7 3.44F 0.50
20 120 116 100F 6 1.89F 0.04
30 144 133 74F 6 0.86F 0.01
a Liposome size determined by QELS before and after size exclusion
chromatography.
b Measurements determined by trapped 14[C]-lactose added during
sample rehydration.
c Measurements determined by internal and external concentrations of
14[C]-methylamine after 1-h incubation at 37 jC.
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dox/Amol lipid) min 1) as compared to liposomes prepared
without cholesterol. It should be noted that previous studies
have shown that cholesterol decreases the partitioning of
ethanol in membranes, predominantly at lower temperatures
[39] and thus addition of ethanol to liposomes prepared with
45 mol% cholesterol had a minimal effect on doxorubicin
loading rates. In the presence of ethanol (10%, v/v), DSPC/
CH/DSPE-PEG2000 liposomes exhibited an initial drug
loading rate of 2.4 (nmol dox/Amol lipid) min 1, a rate
that was three-fold lower than that observed for DSPC/
DSPE-PEG2000 liposomes.Fig. 5. Influence of ethanol on liposomes structure. Cryo-TEM electron micrograp
establishment of a transmembrane pH gradient (pH 4 inside, 7.4 outside). In the p
with polyhedron shapes, were observed. At 20% ethanol, some open liposomes (O
(S) were observed. Bar represents 200 nm.3.5. Optimal ethanol concentration for drug loading in
liposomes
In order to determine the optimal ethanol concentration
for doxorubicin loading into DSPC/DSPE-PEG2000 lipo-
somes, the effect of increasing ethanol concentrations was
investigated by measuring doxorubicin loading efficiency
after a 1-h incubation at 37 jC (Fig. 4). The highest
encapsulation efficiencies were observed when the lipo-
somes were incubated in 10% to 15% (v/v) ethanol. As
shown in Fig. 4, the encapsulation efficiency was reduced
significantly when the concentration of ethanol was z 20%
(v/v). When the DSPC/DSPE-PEG2000 liposomes were
incubated in the presence of 40% and 50% ethanol, there
was an observed increase in solution viscosity or ‘‘gelling’’
of the sample.
Since more subtle changes in liposome structure may
occur in the presence of V 20% (v/v) ethanol, we assessed
the effect of ethanol addition on liposome size, 14[C]-lactose
retention and the pH gradient used to engender drug loading
and promote drug retention (Table 1). DSPC/DSPE-PEG2000
liposomes were exposed to various concentrations of etha-
nol for 1 h prior to measuring liposome size by quasielastic
light scattering (QELS). DSPC/DSPE-PEG2000 liposomes
exposed to increasing ethanol concentrations all exhibited
minimal increases in mean diameter and polydispersity as
judged by standard deviations. At ethanol concentrations
V 20% (v/v), there was less than a 12% increase in liposome
size. The particle size analysis data suggested that even at
ethanol concentrations z 20% (v/v), the liposomes
physica Acta 1661 (2004) 47–60 53hs were obtained of DSPC/DSPE-PEG2000 (95:5 mole ratio) liposomes after
resence of 0% and 10% ethanol (v/v), lipid bilayers (B), described as intact
L) were present, however, at 30%, open liposomes (OL) and bilayer sheets
Fig. 6. (A) Influence of temperature on ethanol-enhanced loading of
doxorubicin in cholesterol-free liposomes. DSPC/DSPE-PEG2000 (95:5
mole ratio) liposomes (with transmembrane pH gradient, pH 4 inside, 7.4
outside) and doxorubicin (0.2 drug-to-lipid mole ratio) were incubated at
various temperatures; 37 jC (.), 23 jC (q), 4 jC (E). At various time
points, 100-Al aliquots of sample were passed down mini spin columns and
subsequently analyzed for drug and lipid concentrations as described in
Section 2. (B) Influence of lipid concentration on ethanol-enhanced loading
of doxorubicin in cholesterol-free liposomes. DSPC/DSPE-PEG2000 (95:5
mole ratio) liposomes (with transmembrane pH gradient, pH 4 inside, 7.5
outside) were prepared at various lipid concentrations, 5 mM (.), 10 mM
(D), 15 mM (w) and 20 mM (z), and incubated with doxorubicin at 37 jC.
At various time points, 100-Al aliquots of sample were passed down mini
spin columns and subsequently analyzed for drug and lipid concentrations
as described in Section 2.
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distribution. However, a 35% increase in liposome size
was observed at ethanol concentrations of 30% (v/v).
Samples passed down sephadex G-50 columns to remove
residual ethanol exhibited a size that was not significantly
different from the sample prior to chromatography.
The permeability of DSPC/DSPE-PEG2000 lipid mem-
branes in the presence of ethanol was determined using a
radiolabeled 14[C]-lactose trapped marker (Table 1). Lipid
films were rehydrated with HBS (pH 7.4) containing trace
quantities of the radiolabeled lactose and extruded. Lipo-
some samples were incubated with increasing concentra-
tions of ethanol (0–30% v/v) for 60 min and passed down
mini columns to separate retained and free lactose. When
incubated with 30% ethanol (v/v), the percent lactose
retained decreased significantly (P < 0.05), consistent with
the notion that ethanol at this concentration affected
liposome permeability sufficiently to promote release of
the entrapped marker. Radiolabeled markers, such as
lactose, are also used to indicate liposome trap volumes.
In the absence of ethanol, DSPC/DSPE-PEG2000 liposomes
prepared by the extrusion technique through 100-nm pore
size filters exhibited a trapped volume of 1.94F 0.11 Al/
Amol. This value was comparable to previously published
trapped volumes for liposomes prepared by extrusion
through 100-nm pore size filters [40].
Another indication of ethanol-induced increases in li-
posome permeability was provided by measuring the
stability of an imposed transmembrane pH gradient. The
DSPC/DSPE-PEG2000 liposomes used in these studies
were prepared in a pH 4.0 citrate buffer and were subse-
quently exchanged into HBS at pH 7.4. The estimated pH
gradient of > 3 units can be measured using methylamine
as a probe [41]. A measured pH gradient of > 2.7 units
was observed when ethanol concentrations were V 10%
(v/v); however, at higher ethanol concentration (z 20% v/
v), there was a significant (P < 0.05) reduction in the
measured transmembrane pH gradient. Previously pub-
lished data have suggested that the magnitude of the pH
gradient is important in terms of maximizing the efficiency
of doxorubicin loading as well as playing a critical role in
governing drug retention [42]. The decreased loading
efficiencies noted in Fig. 4 at ethanol concentrations
V 20% (v/v) are likely due to ethanol’s effect on collaps-
ing the pH gradient.
Ethanol-induced changes in DSPC/DSPE-PEG2000 lip-
osomes were also assessed by cryo-TEM. The representa-
tive photomicrographs shown in Fig. 5 suggest that the
integrity of liposome structure was maintained in the
presence of 10% ethanol (v/v). However, the measured
decreases in percent lactose retention and pH gradient at
higher ethanol concentrations (z 20%, v/v) could be
directly attributed to a breakdown of liposomes structure
as observed by cryo-TEM. This was evidenced by the
presence of open liposomes (OL) seen when the liposomes
were in 20% (v/v) ethanol as well as OL and bilayer sheets(S) observed when the ethanol concentration was increased
to 30% (v/v).
3.6. Influence of temperature, lipid concentration and
phospholipid acyl chain length on ethanol-enhanced drug
loading rates
The results thus far indicate that increases in the rate of
anthracycline loading into DSPC/DSPE-PEG2000 liposomes
parallel the increases in membrane association. Further, it is
demonstrated that ethanol can be used to enhance the
loading efficiency of doxorubicin, one of the anthracyclines
that exhibit the lowest level of membrane partitioning. This
effect is presumably the result of ethanol-mediated increases
in doxorubicin partitioning. Ethanol-enhanced doxorubicin
loading is temperature- (Fig. 6A) and lipid concentration-
Fig. 7. Effect of phospholipid acyl chain length on ethanol-enhanced loading
of doxorubicin in cholesterol-free liposomes. Liposomes exhibiting a
transmembrane pH gradient (pH 4 inside, pH 7.4 outside) composed of 95%
mole ratio of DPPC, DSPC and DAPC and 5% mole ratio of DSPE-PEG2000
incubated at 20 jC (white bars), 40 jC (grey bars) and 60 jC (black bars)
with doxorubicin (0.2 drug-to-lipid ratio). At various time points, 100-Al
aliquots of sample were passed down mini spin columns and subsequently
analyzed for drug and lipid concentrations as described in Section 2.
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was only enhanced when the temperature was higher than
37 jC. No measurable drug uptake could be observed when
the samples were incubated at 23 or 4 jC (Fig. 6A).
Increased lipid concentration resulted in significantly re-
duced drug loading rates. Further studies indicated that
increasing ethanol concentration at high lipid concentrations
(20 mM) did not significantly improve drug loading rates
(data not shown), a result which suggests the importance of
maintaining optimal ethanol concentrations as well as eth-
anol-to-lipid ratios.
Additional studies, shown in Fig. 7, demonstrated that
doxorubicin could be loaded in cholesterol-free liposomes
prepared with phospholipids of varying acyl chain lengths.
These results illustrate three important points. First, as
indicated in Section 3.1, doxorubicin loading efficiencies
in the absence of ethanol increase as the loading temper-
ature increases. Thus, for DSPC/DSPE-PEG2000 and
DAPC/DSPE-PEG2000 liposomes, doxorubicin encapsula-
tion efficiencies of > 95% were achieved when the incu-
bation temperature is held at 60 jC (filled bars). For
DAPC/DSPE-PEG2000 liposomes, doxorubicin encapsula-
tion efficiencies of 58% and 98% were achieved at 40 jC
(grey bars) and 60 jC (filled bars), respectively. These
temperatures are well below the Tc of DAPC and again
illustrate the importance of drug partitioning behaviour in
determining drug loading attributes. Second, doxorubicin
loading into DPPC/DSPE-PEG2000 (Tcf 41 jC), DSPC/
DSPE-PEG2000 (Tcf 55 jC) and DAPC/DSPE-PEG2000
(Tcf 66 jC) liposomes increased as temperature was
increased, however, decreased at temperatures above the
respective Tc of each liposome formulation. When loading
was completed in the presence of 10% ethanol, encapsu-
lation efficiencies of all three formulations significantly
improved (two- to three-fold) at 40 jC (grey bars). Both
DSPC and DAPC formulations achieved greater than 98%
trapping efficiencies. Third, the loading efficiencies of
doxorubicin into DPPC/DSPE-PEG2000 liposomes were in
general poor. The addition of 10% (v/v) ethanol to the
DPPC/DSPE-PEG2000 liposomes, however, did increase
the encapsulated efficiencies more than twofold at both
20 and 40 jC. It is likely that improvements in doxoru-
bicin loading into DPPC/DSPE-PEG2000 liposomes could
be achieved if the loading temperature and ethanol con-
centration are carefully selected.
3.7. Influence of ethanol on release of entrapped doxor-
ubicin in vivo
The use of ethanol to enhance doxorubicin loading into
DSPC/DSPE-PEG2000 liposomes may be of limited interest
if residual ethanol incorporated in the lipid bilayers ad-
versely effects the release of entrapped agents in vivo.
Thus, a PK study was completed to determine whether in
vivo release of doxorubicin was altered if drug loading
was completed in the presence of 10% (v/v) ethanol.Liposomes were prepared as described in Section 2 and
loaded to achieve a 0.2 drug-to-lipid mole ratio. Prior to
injection, the outside buffer was exchanged using tangen-
tial flow dialysis in an effort to remove as much of the
residual ethanol as possible. Subsequently, the liposomes
were injected intravenously in the lateral tail vein of
female Balb/c mice at a dose of 165 Amol/kg lipid and
33 Amol/kg (20 mg/kg) doxorubicin. The plasma elimina-
tion profile of doxorubicin and lipid, as well as the
calculated drug-to-lipid mole ratio in the plasma compart-
Fig. 8. Plasma elimination of liposomal doxorubicin: comparison of drug
release from samples prepared in the absence (o) and presence (.) of
10% (v/v) ethanol. DSPC/DSPE-PEG2000 (95:5 male ratio) liposomes
radiolabeled with 3[H]-CHE were administered intravenously via the
dorsal tail vein of female Balb/c mice at an approximate dose of 33 Amol/
kg doxorubicin and 165 Amol/kg total lipid (0.2 drug-to-lipid mole ratio).
Blood was collected at 0.25, 0.5, 1, 2, 4 and 24 h. Plasma was prepared
and aliquots were assayed for lipid and doxorubicin concentration as
described in Section 2. Each data point represents standard deviations of
three mice.
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were observed in the elimination profiles of the liposomal
drugs prepared in the absence (open symbols) or presence
(filled symbols) of ethanol. Calculated mean plasma
AUC0–24 h for doxorubicin encapsulated in liposomes
prepared with and without ethanol was 9.8 and 11.4 Amol
h ml 1, respectively. Approximately 39% of the total
injected doxorubicin remained in circulation 24 h postdrug administration. Further, the measured drug-to-lipid
mole ratios were not significantly different at any time
points evaluated. These results clearly demonstrate that the
use of ethanol to enhance loading of doxorubicin below
the phase transition of the bulk phospholipid is a poten-
tially useful method that will not compromise in vivo drug
release attributes.4. Discussion
The delicate balance between retention and release of
therapeutic agents entrapped in liposomes is established as
an important factor governing the therapeutic and toxic
effects of liposomal drugs. Altering lipid membrane com-
position with the specific goal of optimizing permeability to
achieve enhanced drug bioavailability following adminis-
tration has been extensively explored. For example, lip-
osomes have been engineered to undergo changes affecting
drug release in response to pH [43], phospholipase exposure
[44,45] and temperature [46] in an effort to achieve im-
proved local drug bioavailability. The behaviour of many of
these formulations is dependent on use of liposomes with
little or no cholesterol. Removal of cholesterol has intro-
duced problems related to drug loading, liposome stability,
liposome–protein binding, liposome elimination and in vivo
drug release following i.v. injection. The incorporation of
PEG-modified lipids into pure PC liposomes effectively
overcomes problems associated with liposome elimination
[47–49]. We have also shown that certain drugs are actually
retained better in liposomes that lack cholesterol [5]. The
general utility of such liposomes will depend, however, on
defining methods which facilitate drug loading and manu-
facturing, particularly since the stability of these liposomes
is much more dependent on temperature. If pH gradient-
based drug loading methods are being considered, one
obvious approach is to select a drug that loads efficiently
into cholesterol-free liposomes at incubation temperatures
below the Tc of the bulk phospholipids. For example,
idarubicin loads efficiently into DSPC/DSPE-PEG2000 lip-
osomes, which exhibit a transmembrane pH gradient, at 40
jC (see Fig. 1A). In contrast, doxorubicin, an anthracycline
that partitions less efficiently into DSPC/DSPE-PEG2000
membranes, loads very slowly at 40 jC. Loading of
doxorubicin is improved as the incubation temperature
increases, however, the stability of the cholesterol-free lip-
osomes is compromised at temperatures above the Tc of the
bulk phospholipids.
If effective drug loading at temperatures below the Tc
of the bulk phospholipids is dependent in part on drug
partitioning, then we anticipated that improved loading
could be achieved through use of agents that could
enhance drug partitioning and/or membrane permeability,
provided that this did not adversely affect liposome sta-
bility. In this study, we have increased doxorubicin lipo-
somal membrane association with ethanol to effectively
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with 5 mol% PEG-conjugated DSPE. Ethanol has previ-
ously been shown to increase the disorder of lipid bilayers
[50,51], and decrease hydration of phospholipids, thereby
enhancing permeability. The rationale for using ethanol (or
other short-chain alcohols) during drug loading is three-
fold. First, to improve the loading rates of drugs that are
not sufficiently hydrophobic to permeate the bilayer;
second, to increase permeability of lipid membranes com-
posed of long acyl chains (greater than C:18); third, to
increase the total drug encapsulation levels within lip-
osomes (for example, DPPC cholesterol-free liposomes)
loaded at fixed temperatures well below the Tc of the bulk
phospholipid. The studies performed in this report con-
firmed that drug loading rates below the Tc of the bulk
phospholipid were correlated with the hydrophobicity of
the drug. Idarubicin, for example, was the most hydropho-
bic anthracycline and optimal loading of this drug could be
achieved at 40 jC in DSPC/DSPE-PEG2000 liposomes.
Less hydrophobic agents, such as doxorubicin, required
higher temperatures to increase drug loading rates. The
results presented (see Figs. 2–4) clearly demonstrated that
ethanol addition could improve doxorubicin loading effi-
ciencies at temperatures below the Tc of the bulk phospho-
lipids. Liposomes composed of long acyl phospholipids are
not commonly considered for drug delivery purposes, in
part because of difficulties in both preparation and drug
loading. Based on our studies, the addition of ethanol will
provide opportunities to investigate the applicability of
novel drugs encapsulated within formulations containing
long acyl chain phospholipids.
Our studies indicated that DPPC cholesterol-free lipo-
somes exhibited a lower capacity for doxorubicin encapsu-
lation. Others have shown that the thermosensitive
liposomal formulation, DPPC/DSPE-PEG2000 with small
amounts of lyso PC (developed by Needham and associ-
ates), also has a low drug encapsulation capacity. Loading
efficiencies of > 98% can only be achieved for 0.05 drug-
to-lipid weight ratios when encapsulated below the Tc of the
membrane and this formulation cannot be effectively loaded
above the phase transition temperature (Ref. [52], Ickenstein
L, unpublished results). We believe that methods relying on
use of ethanol to improve drug loading efficiencies may
solve some of the problems that have been encountered
when developing these drug-loaded thermosensitive liposo-
mal formulations.
Concerns regarding the use of ethanol to improve pH
gradient-based loading of more hydrophilic drugs into
DSPC/DSPE-PEG2000 have been addressed. At concentra-
tions V 15% (v/v) ethanol, liposome size, retention of a
trapped aqueous marker, and stability of an imposed pH
gradient were not significantly changed (see Table 1). At
concentrations z 20% (v/v), the presence of open liposomes
and bilayer sheets were evident by cryo-TEM (see Fig. 5)
and there was a significant reduction in the magnitude of an
imposed 3.5 unit pH gradient. The reduction of [H+]gradient at high ethanol concentrations may be due to either
an overall change in the membrane permeability of all
liposomes or attributed to a decrease in the number of
liposomes available to maintain a pH gradient due to
dissolution of the lipid bilayer. The most obvious change
in DSPC/DSPE-PEG2000 liposomes occurred at ethanol
concentrations > 30% (v/v).
Our studies indicated that both drug loading rates and
liposomal membrane association could predict the in vivo
stability of a drug encapsulated in a particular liposome
formulation. The relationships observed are qualified when
drugs of a similar structure or family are compared and
examined in the same lipid composition, however there are
some inconsistencies. For example, increased drug parti-
tioning of idarubicin in cholesterol-free as compared to
cholesterol-containing liposomes (Fig. 2) would suggest
that there would be increased drug loading rates and drug
release in vivo for cholesterol-free liposomes, which is not
the case. Faster drug loading rates were observed in
cholesterol-containing liposomes (Fig. 3) while enhanced
retention of idarubicin in vivo was observed in cholesterol-
free liposomes [5]. These particular inconsistencies can be
explained by differences in membrane order and fluidity
between DSPC cholesterol-free and cholesterol-containing
liposomes. Furthermore, Madden et al. [53] performed a
survey of many drugs and analyzed drug uptake rates in
egg PC vesicles, and determined that drug uptake could
not be predicted on log octanol/water partition coefficients
alone. Taken together, these observations highlight the
importance of other parameters involved in both drug
uptake into and release from liposomes including lipid
membrane order, drug solubility (aqueous and membrane),
drug membrane partitioning, drug electrostatic and hydro-
phobic interactions. There should be a concerted effort to
tease out each of these factors and their contribution to
both drug loading and release from liposomes. It would be
quite valuable if one could establish high throughput
assays capable of predicting the stability of drug liposomes
formulations in an effort to decrease the trial and error
approach currently used.
One of the principal questions arising from these studies
is how does ethanol enhance doxorubicin loading rates,
allowing the transfer of doxorubicin from the external
medium into the aqueous core of the membrane, while
maintaining the proton gradient? One potential mechanism
involves increasing the interaction of doxorubicin with
liposomal membranes, thereby improving drug loading
rates. As the elimination profiles of doxorubicin loaded
with and without ethanol were not significantly different,
it suggests that most of the residual ethanol was removed.
Therefore, increased doxorubicin liposomal membrane as-
sociation was preferentially introduced during drug loading
but reduced (by the removal of ethanol) prior to PK
analysis. Ethanol–lipid membrane interactions have been
extensively studied. There is still a debate on where ethanol
resides in the membrane, and the nature of the interaction,
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indicated that ethanol resides at the lipid/water interface
near the head groups, with a small amount partitioned in the
bilayer core [17,20]. Regarding lipid interdigitation, an
increase in the incorporation of ethanol can induce this
polymorphic change in membrane structure [29,55–57].
Interdigitation is described as a consequence of the dis-
placement of water from the interfacial region [24], resulting
in a disordering effect on lipid packing [50] and intercala-
tion of phospholipids acyl chains from opposing leaflets
[58]. The presence of interdigitation domains would likely
increase bilayer permeability in both directions and does not
explain how the incorporation of low levels of ethanol in
lipid membranes resulted in increased doxorubicin drug
loading rates while maintaining the pH gradient. A more
plausible explanation for the effects of ethanol on selective
increases in drug permeability pertains to asymmetric dis-
tribution of ethanol in lipid bilayers. Most studies have
clearly indicated that short-chain alcohols are positioned at
the lipid/water interface of the membrane [59]. Studies
performed by Heerklotz [60] demonstrated that membrane
stress and permeabilization of bilayers from solutes were
induced by asymmetric incorporation of compounds. Asym-
metric ethanol incorporation may explain why doxorubicin
could permeate into the aqueous space of the liposomes,
while proton permeability was not increased substantially.
Furthermore, if the majority of ethanol partitioned within
the outer leaflet of the bilayer, ethanol would be relatively
easily removed and would not affect doxorubicin release
from the liposomes.
In summary, the addition of ethanol to preformed lip-
osomes is an effective strategy to increase drug membrane
association and membrane permeability, allowing loading of
drugs that are not sufficiently hydrophobic to cross lipid
membranes on a practical time scale. At low ethanol
concentrations, initial drug loading rates were significantly
improved without affecting the in vivo behaviour of the
resulting liposomes. Ethanol enhanced drug loading will be
of particular interest when utilizing thermosensitive liposo-
mal formulations, heat-labile drugs or conditions (such as
acidic pH) that promote rapid phospholipid degradation at
high temperatures. The studies reported here highlight a few
advantages of this method. Importantly, we anticipate that
similar approaches may be used to improve loading of other
anticancer drugs into cholesterol-free liposomes.Acknowledgements
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